

Name Participants of WG3	Jelizaveta Sokolovska
Affiliation	University of Latvia, Faculty of Medicine
Scientific expertise, up to 5 key words	diabetes, complications of diabetes, endocrinology, clinical research, nutrition
Motivation for participation in WG3	to build collaborations with basic scientists/other clinicians providing the samples of well-characterized patients (with diabetes mainly) for investigation of Nrf2 pathways.
Short narrative biosketch, including scientific background/ education/major achievements etc.	I'm MD, PhD, certified and practicing internist and endocrinologist. PhD in 2014 on modulation of nitric oxide hyperproduction and expression of glucose transporters in rat models of diabetes in different tissues. Since 2013 – only clinical research. Co-author of 30 scopus publications, H-index 10.
Current research topics/ongoing projects	1)“Novel biomarkers of diabetic retinopathy: epigenetic modifications of genes of ubiquitine- proteasome system, telomere length and proteasome concentration. 2019-2021. Mutual funds Taiwan-Latvia-Lithuania, leading researcher, PI in Latvia. 2)ERDF project “Postdoctoral research aid”, Nr. 1.1.1.2/16/I/001. 2020-2023. Intestinal inflammation as a potentially modifiable risk factor for complications in type 1 diabetes. J. Sokolovska – postdoctorate 3)Project of Latvian Science Council program of Fundamental and applied research projects 2021-2023. “Dissecting the associations between glucose variability, intestinal derangements and progression of diabetic nephropathy in type 1 diabetes”. J. Sokolovska – PI 4)Baltic Research Program 2021-2023. Integrated model for personalized diabetic retinopathy screening and monitoring using risk-stratification and automated AI-based fundus image analysis (PerDiRe). J. Sokolovska – PI in Latvia, Latvian partner is the coordinator of the consortium 5) longitudinal Latvian diabetic nephropathy study (in type 1 diabetes, ongoing since 2013)
Nfr2-related methodologies/ infrastructure/ equipment	via collaboration of other structures of University of Latvia, a variety of molecular biology and biochemical methods is available. Recently we performed methylation analysis of KEAP1 gene in patients with different diabetic retinopathy status and type 1 diabetes.
Available sample collections/datasets; interested in sharing; yes/no	1) type 1 diabetes approx. 500, approx.. 150 of them with regular follow-ups. Datasets – anthropometric measures, history of diabetes and complications, clinical blood chemistry, mononuclear cell DNA breaks in 70 patients, nitric oxide and its metabolites in 70 patients, angiopoietin 2 and neuropeptide Y in 300 patients, diet data (food frequency and 3-day diet record) in 74 patients, data on lifestyle and psychosocial data, GWAS in 200 patients 2) generally healthy adults 50 - anthropometric measures,clinical blood chemistry, diet data (food frequency and 3-day diet record) 3) type 2 diabetes – different datasets, including before and after physical activity intervention in 56 patients, basic data and blood

	<p>chemistry dataset more than 400, GWAS and faecal microbiome data in a subset of patients</p> <p>4) via collaboration with the Latvian biobank – other patient groups available (thyroid disease, oncology etc)</p>
Available cohorts/ ongoing/planned human studies/grant applications	type 1 diabetes, type 2 diabetes
Interested in STSM: outgoing/hosting (year 1/later); yes/no	yes